

Corrie J. Yackulic
CORRIE YACKULIC LAW FIRM PLLC
110 Prefontaine Place South, Suite 304
Seattle, Washington 98104
Tel. 206.787.1915
Fax. 206.299.9725
Corrie@cjylaw.com

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF WASHINGTON

STEPHANIE WOODCOCK,

Plaintiff,

v.

JOHNSON AND JOHNSON; and ETHICON,
INC.,

Defendants.

Case No.

COMPLAINT

JURY TRIAL DEMANDED

I. CIVIL ACTION COMPLAINT

Plaintiff STEPHANIE WOODCOCK, by and through her counsel, brings this Complaint against Defendants ETHICON, INC., and JOHNSON & JOHNSON (collectively, “Defendants”, as the context may require) for injuries suffered as a result of defective pelvic mesh products designed, manufactured and marketed by Defendants, and implanted in Plaintiff. In support, Plaintiff states and avers as follows:

II. PARTIES

1. Plaintiff Stephanie Woodcock is and was, at all relevant times, a resident of Yakima in the state of Washington.

COMPLAINT WITH JURY DEMAND
PAGE 1

Corrie Yackulic Law Firm PLLC
110 Prefontaine Place South, Suite 304
Seattle, Washington 98104
Tel. 206.787.1915
Fax. 206.299.9725

2. Defendant, Ethicon, Inc. is a wholly owned subsidiary of Defendant Johnson & Johnson and is located in Somerville, New Jersey.

3. Defendant Johnson & Johnson is a corporation, and according to its website, the world's largest and most diverse medical devices and diagnostics company, with its worldwide headquarters located at One Johnson & Johnson Plaza, New Brunswick, New Jersey.

4. Defendants ETHICON, INC. and JOHNSON & JOHNSON share many of the same officers, directors and operations; and maintain ownership in the assets and/or liabilities relating to the design, manufacture, marketing, distribution and sale of the medical device line at issue in this litigation and shall be referenced collectively hereinafter as "Defendants".

5. All acts and omissions of each Defendant as described herein were done by its agents, servants, employees and/or owners, acting in the course and scope of their respective agencies, services, employments and/or ownership.

III. JURISDICTION AND VENUE

6. Damages sought in this matter are in excess of \$75,000.00. Subject matter jurisdiction is proper pursuant to 28 U.S.C. § 1332.

7. This Court has subject matter jurisdiction over the parties pursuant to 28 U.S.C. § 1332(a) because the parties are citizens of different states and the amount in controversy exceeds \$75,000.00, exclusive of interest and costs.

8. Venue is proper in the Eastern District Court of Washington pursuant to 28 U.S.C. § 1391 because a substantial part of the events giving rise to this claim occurred in this district.

9. Defendants conducted substantial business in the State of Washington and in this

1 District, distribute Pelvic Mesh Products in this District, receive substantial compensation and
2 profits from sales of Pelvic Mesh Products in this District, and made material omissions and
3 misrepresentations and breaches of warranties in this District so as to subject them to *in*
4 *personam* jurisdiction in this District.
5

6 10. Defendants conducted business in the State of Washington through sales
7 representatives and because Defendants were engaged in testing, developing, manufacturing,
8 labeling, marketing, distributing, promotion and/or selling, either directly or indirectly, and/or
9 through third parties or related entities, Pelvic Mesh Products in the State of Washington; thus,
10 there exists a sufficient nexus between Defendants' forum contacts and the Plaintiff's claims to
11 justify assertion of jurisdiction in Washington.
12

13 11. Consistent with the Due Process Clause of the Fifth and Fourteenth Amendments,
14 this Court has *in personam* jurisdiction over Defendants, because Defendants are present in the
15 State of Washington such that requiring an appearance does not offend traditional notions of fair
16 play and substantial justice.
17

18 **IV. DEFENDANTS' PELVIC MESH PRODUCTS**

19 12. In or about October, 2002, the Defendants began to market and sell a product
20 known as Gynemesh, for the treatment of medical conditions in the female pelvis, primarily
21 pelvic organ prolapse and stress urinary incontinence. All references to Gynemesh include all
22 variations of or names used for Gynemesh, including but not limited to Gynemesh PS.
23

24 13. Gynemesh was derived from a product known as Prolene Mesh, which was used
25 in the treatment of medical conditions in the female pelvis, primarily pelvic organ prolapse and
26 stress urinary incontinence. Prolene Mesh was derived from Defendants' prolene mesh hernia
27

1 product, and was and is utilized in the treatment of medical conditions in the female pelvis,
2 primarily pelvic organ prolapse and stress urinary incontinence. All references to Prolene
3 Mesh include all variations of Prolene Mesh, including but not limited to Prolene Soft Mesh.
4

5 14. In or about September, 2005, the Defendants began to market and sell a product
6 known as Prolift, for the treatment of medical conditions in the female pelvis, primarily pelvic
7 organ prolapse and stress urinary incontinence. The Prolift was and is offered as an anterior,
8 posterior, or total repair system, and all references to the Prolift include by reference all
9 variations.
10

11 15. In or about May, 2008, the Defendants began to market and sell a product known
12 as Prolift+M, for the treatment of medical conditions in the female pelvis, primarily pelvic organ
13 prolapse and stress urinary incontinence. The Prolift+M was and is offered as an anterior,
14 posterior, or total repair system, and all references to the Prolift+M include by reference all
15 variations.
16

17 16. The Defendants market and sell a product known as TVT, for the treatment of
18 stress urinary incontinence in females. The TVT has been and is offered in multiple variations
19 including, but not limited to, the TVT, TVT-O, and TVT-S, and all references to the TVT include
20 by reference all variations.
21

22 17. The products known as Prolene Mesh, Gynemesh,, Prolift, Prolift+M, and TVT,
23 as well as any as yet unidentified pelvic mesh products designed and sold for similar purposes,
24 inclusive of the instruments and procedures for implantation, are collectively referenced herein
25 as Defendants' Pelvic Mesh Products or the Pelvic Mesh Products.
26

27 18. Defendants' Pelvic Mesh Products were designed, patented, manufactured,

1 labeled, marketed, and sold and distributed by the Defendants, at all times relevant herein.

2 **V. FACTUAL BACKGROUND**

3
4 19. Plaintiff underwent robotic assisted laparoscopic sacrocolpopexy and cystoscopy
5 with placement of Gynemesh, Product No. GPSXL3; Lot#DAP067 on October 13, 2011 at
6 OHSU in Portland Oregon.

7 20. By April 10, 2012, Plaintiff Stephanie Woodcock's mesh had failed, and she
8 prolapsed again. She underwent attempted removal of the mesh with cystocele repair, and
9 rectocele repair at Yakima Valley Memorial Hospital in Yakima, Washington.

10 21. By February 22, 2016, Plaintiff Stephanie Woodcock was experiencing mesh
11 exposure and extreme pain with intermittent catheterization, dyspareunia and mixed urinary
12 incontinence, urge incontinence, and fecal incontinence.

13
14 22. On March 22, 2016 Stephanie Woodcock underwent surgery to remove the
15 exposed mesh in the right posterior and apical vagina, a cystoscopy and vaginotomy at
16 University of Washington Medical Center in Seattle, Washington.

17 23. The severe problems that Plaintiff suffered after her implant surgery were caused
18 by the not reasonably safe design and manufacture of the Medical Device that was surgically
19 implanted in her. In addition, the revision surgery that Plaintiff underwent were necessitated by
20 the not reasonably safe design and manufacture of the Medical Device used in the Plaintiff's
21 original procedure.

22
23 24. Plaintiff is not alone in sustaining injury as a result of the not reasonably safe
24 design and manufacture of Defendants' Medical Device. The FDA has received thousands of
25 reports of women who were injured or killed after being implanted with devices similar to that
26

1 used in Plaintiff's original implant procedure.

2 25. As discussed below, the FDA responded to the volume of reports of injuries
3 arising from the implant of surgical mesh by issuing a "Public Health Notification" relating to
4 the use of these devices. In July 2011, the FDA also took the unusual step of issuing an "update"
5 to this Public Health Notification. In 2019 the FDA banned the further sale of transvaginal mesh
6 slings for pelvic organ prolapse. These publications confirm the dangerous nature of the
7 Defendants' mesh products.
8

9 26. As a result of having the Product implanted in her, Plaintiff has experienced
10 significant mental and physical pain and suffering, has sustained permanent injury and
11 permanent and substantial physical deformity and has suffered financial or economic loss,
12 including, but not limited to, obligations for medical services and expenses.
13

14 27. Defendants' Pelvic Mesh Product has been marketed to the medical community
15 and to patients as a safe, effective, reliable, medical device; implanted by safe and effective,
16 minimally invasive surgical techniques for the treatment of medical conditions, primarily pelvic
17 organ prolapse and stress urinary incontinence, and as safer and more effective as compared to
18 the traditional products and procedures for treatment, and other competing pelvic mesh products.
19

20 28. The Defendants have marketed and sold the Defendants' Pelvic Mesh Product to
21 the medical community at large and patients through carefully planned, multifaceted marketing
22 campaigns and strategies. These campaigns and strategies include, but are not limited to direct
23 to consumer advertising, aggressive marketing to health care providers at medical conferences,
24 hospitals, private offices, and include the provision of valuable consideration and benefits to
25 health care providers. Also utilized are documents, brochures, websites, and telephone
26

1 information lines, offering exaggerated and misleading expectations as to the safety and utility
2 of the Defendants' Pelvic Mesh Product.

3
4 29. Contrary to the Defendants' representations and marketing to the medical
5 community and to the patients themselves, the Defendants' Pelvic Mesh Product has high
6 failure, injury, and complication rates, fails to perform as intended, requires frequent and often
7 debilitating re-operations, and has caused severe and irreversible injuries, conditions, and
8 damage to a significant number of women, including the Plaintiff.

9
10 30. The Defendants have consistently underreported and withheld information about
11 the propensity of Defendants' Pelvic Mesh Product to fail and cause injury and complications,
12 and have misrepresented the efficacy and safety of the Product, through various means and
13 media, actively and intentionally misleading the FDA, the medical community, patients, and the
14 public at large.

15 31. Defendants have known and continue to know that their disclosures to the FDA
16 were and are incomplete and misleading; and that the Defendants' Pelvic Mesh Product was and
17 is causing numerous patients' severe injuries and complications. The Defendants suppressed this
18 information and failed to accurately and completely disseminate or share this and other critical
19 information with the FDA, health care providers, or the patients. As a result, the Defendants
20 actively and intentionally misled and continue to mislead the public, including the medical
21 community, health care providers and patients, into believing that the Defendants' Pelvic Mesh
22 Product was and is safe and effective, leading to the prescription for and implantation of the
23 Pelvic Mesh Product into the Plaintiff.
24

25 32. Defendants failed to perform or rely on proper and adequate testing and research
26

1 in order to determine and evaluate the risks and benefits of the Defendants' Pelvic Mesh Product.

2 33. Defendants failed to design and establish a safe, effective procedure for removal
3 of the Defendants' Pelvic Mesh Product; therefore, in the event of a failure, injury, or
4 complications it is impossible to easily and safely remove the Defendants' Pelvic Mesh Product.
5

6 34. Feasible and suitable alternative designs as well as suitable alternative procedures
7 and instruments for implantation and treatment of stress urinary incontinence, pelvic organ
8 prolapse, and similar other conditions have existed at all times relevant as compared to the
9 Defendants' Pelvic Mesh Product.

10 35. The Defendants' Pelvic Mesh Product was at all times utilized and implanted in
11 a manner foreseeable to the Defendants.
12

13 36. The Defendants have at all times provided incomplete, insufficient, and
14 misleading training and information to physicians, in order to increase the number of physicians
15 utilizing the Defendants' Pelvic Mesh Product, and thus increase the sales of the Product, and
16 also leading to the dissemination of inadequate and misleading information to patients, including
17 Plaintiff.
18

19 37. The Pelvic Mesh Product implanted into the Plaintiff was in the same or
20 substantially similar condition as it was when it left the possession of Defendants, and in the
21 condition directed by and expected by the Defendants.

22 38. The injuries, conditions, and complications suffered due to Defendants' Pelvic
23 Mesh Product include but are not limited to mesh erosion, mesh contraction, infection, fistula,
24 inflammation, scar tissue, organ perforation, dyspareunia, blood loss, neuropathic and other
25 acute and chronic nerve damage and pain, pudendal nerve damage, pelvic floor damage, pelvic
26

1 pain, urinary and fecal incontinence, prolapse of organs, and in many cases the women have
2 been forced to undergo intensive medical treatment, including but not limited to operations to
3 locate and remove mesh, operations to attempt to repair pelvic organs, tissue, and nerve damage,
4 the use of pain control and other medications, injections into various areas of the pelvis, spine,
5 and the vagina, and operations to remove portions of the female genitalia, and injuries to
6 Plaintiff's intimate partners.
7

8 39. Despite Defendants' knowledge of these catastrophic injuries, conditions, and
9 complications caused by their Pelvic Mesh Product, the Defendants have, and continue to
10 manufacture, market, and sell the Product, while continuing to fail to adequately warn, label,
11 instruct, and disseminate information with regard to the Defendants' Pelvic Mesh Product, both
12 prior to and after the marketing and sale of the Product.
13

14 **VI. FIRST CAUSE OF ACTION**
15 **WASHINGTON PRODUCT LIABILITY ACT**

16 40. Plaintiff incorporates by reference all prior paragraphs of this Complaint as if
17 fully set forth herein and further alleges as follows:

18 41. At all times relevant to this litigation, Defendants engaged in the business of
19 testing, developing, designing, manufacturing, marketing, selling, distributing, and promoting
20 its medical device products.
21

22 42. At all times relevant to this litigation, Defendants designed, researched,
23 developed, manufactured, produced, tested, assembled, labeled, advertised, promoted,
24 marketed, sold, and distributed the medical device used by Plaintiff as described above.

25 43. At all times relevant to this litigation, Defendants' medical device was expected
26

1 to reach and did reach the intended consumers, handlers, and users or other persons coming into
2 contact with these products in Washington and throughout the United States, including Plaintiff,
3 without substantial change in their condition as designed, manufactured, sold, distributed,
4 labeled, and marketed by Defendants.
5

6 44. In violation of the Washington Products Liability Act (“WPLA”), RCW 7.72, et
7 seq., at all times relevant to this action, at the time Defendants’ medical device left control of
8 Defendants, it was defective and not reasonably safe. These defects include, but are not limited
9 to, the following:
10

- 11 a) Defendants are strictly liable for Plaintiff’s injuries and damages
12 because at the time of manufacture, and at the time Defendants’
13 medical device left control of Defendants, the likelihood that the
14 medical device would cause injury or damage similar to that suffered
15 by Plaintiff, and the seriousness of such injury or damage had been
16 known by Defendants and outweighed the burden on Defendants to
17 design a product that would have prevented Plaintiff’s injuries and
18 damages and outweighed the adverse effect that an alternative design
19 that was practical and feasible would have on the usefulness of the
20 subject product.
21
- 22 b) Defendants’ medical device is unsafe to an extent beyond that which
23 would be contemplated by an ordinary consumer.
24
- 25 c) The medical device manufactured and/or supplied by Defendants was
26 defective in design in that, an alternative design and/or formulation
27 exists that would prevent severe and permanent injury. Indeed, at the
time that Defendants designed their medical device, the state of the
industry’s scientific knowledge was such that a less risky design or
formulation was attainable.
- d) The medical device was not reasonably safe in design under the WPLA.
- e) The medical device manufactured and/or supplied by Defendants was
not reasonably safe because Defendants did not provide an adequate
warning or instruction about the product. At the time the medical device

1 left Defendants' control, the device possessed dangerous
2 characteristics and Defendants failed to use reasonable care to provide
3 an adequate warning of such characteristics and their danger to users
4 and handlers of the product. The medical device is not safe and cause
5 severe and permanent injuries. The medical device was not reasonably
safe because the warning was inadequate, and Defendants could have
provided adequate warnings or instructions.

6 f) The medical device that was manufactured and/or supplied by
7 Defendants was not reasonably safe because adequate warnings or
8 manufacturer instructions were not provided after the medical device
was manufactured and when Defendants learned of, or should have
learned of, the dangers connected with the medical device.

9 g) The medical device manufactured and/or supplied by Defendants was
10 not reasonably safe because it did not conform to an express warranty
11 made by Defendants regarding the product's safety and fitness for use.
12 Defendants expressly warranted that the medical device was safe and
13 fit for their intended purposes, that it was of merchantable quality, that
14 it was not produce any dangerous side effects, that they were
adequately tested, and that the device was safe to human health and the
15 environment, and effective, fit, and proper for its intended
16 use. Defendants did not disclose the material risks that its medical
17 device could cause severe and permanent injury. Defendants' express
warranty induced Plaintiff to use the device, and Plaintiff's damages
were proximately caused because Defendants' express warranty was
untrue. The mesh product was not reasonably safe because of
nonconformity to express warranty under the WPLA.

18 45. As a direct and proximate result of Defendants placing their its defective medical
19 device into the stream of commerce, Plaintiff suffered grave injuries, and endured physical and
20 emotional pain and discomfort, as well as economic hardship, including considerable financial
21 expenses for medical care and treatment and other damages further discussed in herein.

22
23 46. As a direct and proximate result of Defendants placing its defective medical
24 device into the stream of commerce, Plaintiff suffered grave injuries, and endured physical and
25 emotional pain and discomfort, as well as economic hardship, including considerable financial
26

1 expenses for medical care and treatment and other damages further discussed in herein.

2 WHEREFORE, Plaintiff demands judgment against Defendants, and each of them,
3 individually, and jointly and severally , and requests compensatory and punitive damages,
4 together with interest, costs of suit, attorneys' fees, and such further relief as the Court deems
5 equitable and just.
6

7 **VII. SECOND CAUSE OF ACTION**
8 **VIOLATION OF THE WASHINGTON CONSUMER PROTECTION ACT**

9 47. Plaintiff realleges and incorporates by reference every allegation of this
10 Complaint as if each were set forth fully and completely herein.

11 48. Plaintiff purchased and used the Defendants' Pelvic Mesh Product primarily for
12 personal use and thereby suffered ascertainable losses as a result of Defendants' actions in
13 violation of the consumer protection laws.

14 49. Had Defendants not engaged in the deceptive conduct described herein, Plaintiff
15 would not have purchased and/or paid for the Defendants' Pelvic Mesh Product, and would not
16 have incurred related medical costs and injury.
17

18 50. Defendants engaged in wrongful conduct while at the same time obtaining, under
19 false pretenses, moneys from Plaintiff for the Pelvic Mesh Product that would not have been
20 paid had Defendants not engaged in unfair and deceptive conduct.

- 21 a) Unfair methods of competition or deceptive acts or practices that were
22 proscribed by law, including the following:
- 23 b) Representing that goods or services has characteristics, ingredients,
24 uses benefits or quantities that they do not have;
- 25 c) Advertising goods or services with the intent not to sell them as
26 advertised; and,

- 1
2 d) Engaging in fraudulent or deceptive conduct that creates a likelihood
3 of confusion or misunderstanding.

4 51. Plaintiff was injured by the cumulative and indivisible nature of Defendants'
5 conduct. The cumulative effect of Defendants' conduct directed at patients, physicians and
6 consumers was to create demand for and sell the Defendants' Pelvic Mesh Product. Each aspect
7 of Defendants' conduct combined to artificially create sales of the Defendants' Pelvic Mesh
8 Product.

9 52. Defendants have a statutory duty to refrain from unfair or deceptive acts or trade
10 practices in the design, labeling, development, manufacture, promotion, and sale of the
11 Defendants' Pelvic Mesh Product.

12 53. Had Defendants not engaged in the deceptive conduct described above, Plaintiff
13 would not have purchased and/or paid for the Product, and would not have incurred related
14 medical costs.

15 54. Defendants' deceptive, unconscionable, or fraudulent representations and
16 material omissions to patients, physicians and consumers, including Plaintiff, constituted unfair
17 and deceptive acts and trade practices in violation of the state consumer protection statutes listed.

18 55. Defendants' actions, as complained of herein, constitute unfair competition or
19 unfair, unconscionable, deceptive or fraudulent acts, or trade practices in violation of state
20 consumer protection statutes, as listed below.

21 56. Defendants have engaged in unfair competition or unfair or deceptive acts or
22 trade practices or have made false representations.

23 57. Under applicable state statutes enacted to protect consumers against unfair,
24

1 deceptive, fraudulent and unconscionable trade and business practices and false advertising,
2 Defendants are the suppliers, manufacturers, advertisers, and sellers, who are subject to liability
3 under such legislation for unfair, deceptive, fraudulent and unconscionable consumer sales
4 practices.
5

6 58. Defendants violated the statutes that were enacted in these states to protect
7 consumers against unfair, deceptive, fraudulent and unconscionable trade and business practices
8 and false advertising, by knowingly and falsely representing that the Defendants' Pelvic Mesh
9 Product was fit to be used for the purpose for which it was intended, when in fact it was defective
10 and dangerous, and by other acts alleged herein. These representations were made in marketing
11 and promotional materials.
12

13 59. The actions and omissions of Defendants alleged herein are uncured or incurable
14 deceptive acts under the statutes enacted in the states to protect consumers against unfair,
15 deceptive, fraudulent and unconscionable trade and business practices and false advertising.
16

17 60. Defendants had actual knowledge of the defective and dangerous condition of
18 the Defendants' Pelvic Mesh Product and failed to take any action to cure such defective and
19 dangerous conditions.
20

21 61. Plaintiff and the medical community relied upon Defendants' misrepresentations
22 and omissions in determining which product and/or procedure to undergo and/or perform (if
23 any).
24

25 62. Defendants' deceptive, unconscionable or fraudulent representations and
26 material omissions to patients, physicians and consumers, constituted unfair and deceptive acts
27 and practices.

1 63. By reason of the unlawful acts engaged in by Defendants, and as a direct and
2 proximate result thereof, Plaintiff has suffered ascertainable losses and damages.

3 64. As a direct and proximate result of Defendants' violations of the states' consumer
4 protection laws, Plaintiff has sustained economic losses and other damages and is entitled to
5 statutory and compensatory, damages in an amount to be proven at trial.
6

7 WHEREFORE, Plaintiff demands judgment against Defendants, and each of them,
8 individually, jointly, severally and in the alternative, and request restitution and disgorgement of
9 profits, together with interest, cost of suit, attorneys' fees, and all such other and further relief as
10 this Court deems just and proper.
11

12 **VIII. PUNITIVE DAMAGES**

13 65. Plaintiff realleges and incorporates by reference every allegation of this
14 Complaint as if each were set forth fully and completely herein.

15 66. The wrongs done by Defendants were aggravated by the kind of malice, fraud,
16 and grossly negligent disregard for the rights of others, the public, and Plaintiff for which the
17 law would allow, and which Plaintiff will seek at the appropriate time under governing law for
18 the imposition of exemplary damages, in that Defendants' conduct, including the failure to
19 comply with applicable Federal standards: was specifically intended to cause substantial injury
20 to Plaintiff; or when viewed objectively from Defendants' standpoint at the time of the conduct,
21 involved an extreme degree of risk, considering the probability and magnitude of the potential
22 harm to others, and Defendants were actually, subjectively aware of the risk involved, but
23 nevertheless proceeded with conscious indifference to the rights, safety, or welfare of others; or
24 included a material representation that was false, with Defendants, knowing that it was false or
25
26

1 with reckless disregard as to its truth and as a positive assertion, with the intent that the
 2 representation is acted on by Plaintiff.

3 67. Plaintiff relied on the representation and suffered injury as a proximate result of
 4 this reliance.
 5

6 68. Plaintiff therefore will seek to assert claims for exemplary damages at the
 7 appropriate time under governing law in an amount within the jurisdictional limits of the Court.

8 69. Plaintiff also alleges that the acts and omissions of named Defendants, whether
 9 taken singularly or in combination with others, constitute gross negligence that proximately
 10 caused the injuries to Plaintiff. In that regard, Plaintiff will seek exemplary damages in an
 11 amount that would punish Defendants for their conduct and which would deter other
 12 manufacturers from engaging in such misconduct in the future.
 13

14 WHEREFORE, Plaintiff demands judgment against Defendants, and each of them,
 15 individually, and jointly and severally , and requests compensatory damages, together with
 16 interest, costs of suit, attorneys' fees, and such further relief as the Court deems equitable and
 17 just.
 18

19 **IX. PRAYER FOR RELIEF**

20 WHEREFORE, Plaintiff demands judgment against Defendants, and each of them,
 21 individually, and jointly and severally, and requests compensatory damages, together with
 22 interest, cost of suit, attorneys' fees, and all such other relief as the Court deems just and proper
 23 as well as:
 24

- 25 A. All general, statutory, and compensatory damages, in excess of the amount
 26 required for federal diversity jurisdiction, and in an amount to fully compensate

- 1 Plaintiffs for all general damages, both past and future;
2 B. All special and economic damages, in excess of the amount required for federal
3 diversity jurisdiction and in an amount to fully compensate Plaintiffs for all of
4 their injuries and damages, past and future;
5 C. Attorneys' fees, expenses, and costs of this action;
6 D. Double or triple damages as allowed by law;
7 E. Punitive and/or exemplary damages;
8 F. Pre-judgment and post-judgment interest in the maximum amount allowed by
9 land; and
10 G. Such further relief as this Court deems necessary, just, and proper.

11 **X. DEMAND FOR JURY TRIAL**

12 Plaintiff demands a trial by jury on all issues so triable.

13 Dated this 9th day of July, 2020.

14 CORRIE YACKULIC LAW FIRM, PLLC

15 /s/ Corrie J. Yackulic

16 Corrie J. Yackulic, WSBA No. 16063
17 110 Prefontaine Place South, Suite 304
18 Seattle, Washington 98104
19 Tel. 206-787-1915
20 Fax. 206-299-9725
21 Corrie@cjylaw.com

22 *Attorney for Plaintiff*